
Stay up-to-date with the latest developments in gene and cell therapy by subscribing to our newsletter.
Featured:
Jun 24 | BioMarin’s AAV5-hFVIII-SQ Gene Therapy Shows Durable Efficacy and Safety at Five Years for Severe Hemophilia A read more »
Jun 24 | Sangamo’s AAV Gene Therapy Shows Promising Kidney & Clinical Benefits for Fabry Disease read more »
Jun 23 | Passage Bio Reports Positive Interim Data from AAV-Based PBFT02 Gene Therapy Trial for FTD-GRN read more »
News:
Jun 24 | Abeona’s COL7A1 Gene Therapy Shows Robust Efficacy in The Lancet-Published RDEB Study read more »
Jun 23 | Fractyl Health’s AAV-Based Rejuva “Smart GLP-1” Gene Therapy Shows Strong Preclinical Data at ADA 2025 read more »
Jun 23 | Cure Rare Disease Advances AAV Gene Therapy for LGMDR9 Following Positive FDA Pre-IND Meeting read more »
Jun 23 | Genprex Presents Promising Preclinical Data on LNP Gene Therapy for Diabetes read more »
Jun 23 | Opus Genetics Secures $2 Million from RD Fund to Advance AAV Gene Therapy for Retinitis Pigmentosa read more »
Jun 23 | First UK Patient Treated with CSL Behring’s AAV Gene Therapy for Hemophilia B read more »
Jun 20 | NSW Government Invests $13.39 Million for Rare Disease and Cancer Therapies read more »
Articles:
Jun 25 | AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice read more »
Jun 25 | Barcoded viral tracing identifies immunosuppressive astrocyte–glioma interactions read more »
Jun 24 | An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis read more »
Jun 24 | Preclinical evaluation of lentiviral gene therapy for adenosine deaminase 2 deficiency (DADA2): engraftment efficiency and biodistribution in humanised NBSGW mice read more »
Jun 24 | Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors read more »
Jun 23 | Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial read more »
Jun 23 | Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications read more »
Jun 20 | LbuCas13a directly targets DNA and elicits strong trans-cleavage activity read more »
Jun 20 | AAV for ovarian cancer gene therapy read more »
Jun 20 | Mixture design as a tool for improving full-to-empty particle ratios across various GOIs in rAAV production read more »
Jun 20 | Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform read more »
Jun 19 | In vivo CAR T cell generation to treat cancer and autoimmune disease read more »
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
